NAGL MedTech™ brings leading-edge medical technology to market through a talented staff of accomplished engineers and specialists. NAGL MedTech™ offers product development support services with access to equipment, systems, or expertise – all or in part – to help you minimize your investment in capital equipment, business systems, and human capital.
Clients can select from our four distinct ELEVATOR® service offerings ranging from off-site project support to full incubation of their company, from conception to commercialization, at the NAGL MedTech™ facility.
Unlike traditional OEM Manufacturers, NAGL MedTech™ has no interest in locking you into long-term manufacturing contracts based on production volumes. Our interest lies in understanding your incubation program and exit strategy, allowing us to plan together how NAGL MedTech™ can best serve your needs throughout the entire project lifecycle. The ELEVATOR® business model allows each client to develop and foster an ongoing relationship based on exceptional medical design and cost-effective solutions.
Our sole focus here at NAGL MedTech™ is to bring leading-edge medical technology ideas to life, through the work of our passionate associates. From neuro-catheter systems, robotic surgery devices, and more, NAGL MedTech™ truly shapes the future through the research, design, and commercialization of industry-changing technology.
We are industry changers. A group of people that come together every day to work towards a better tomorrow for everyone.
To provide The Disney experience to the MedTech industry worldwide.
Provide a path for MedTech companies around the world to meet their business objectives through the innovative service offerings, proprietary development recipes, and cost-effective production capabilities.
- Client Focus
Started Naglreiter Consulting LLC
Expanded staff to 3 associates
Leased 1,000 sq. ft. space and quality system, and opened first operations within Innovia LLC
Moved headquarters to Miramar, expanded to 3,500 sq. ft., and increased associates to 7
Expanded space to 6,000 sq. ft., made $600k in captial investments, initiated NCL quality system development, and increased associates to 13
Expanded space to 10,000 sq. ft., made $800k in additional capital investments, certified the quality system, and increased associates to 25
Made additional capital investments of $700k, validated sterilization cycle, and increased associates to 40
Finalized marketing campaign and increased associates to 56
Expanded Strategic Partnerships and invested an additional $650k in equipment and system integration. Increased associates to 63.
Expanded leased space from 10,000 sq. ft to 17,000 sq. ft.
Made additional $400k investment in two fully incubated companies.
Invested $300k in equipment and system improvements. Associate count hits triple digits – increased to 102.
Reduced workforce head count from 102 to 55 due to COVID-19.
Provided $1M in service loans to incubated companies.
Invested $300K into Endovascular Production Tooling.
Increased workforce head count from 55 to 69 to address rebound in market.
Provided an additional $1.5M in funds to incubated companies.